SCHEMBL6791925

SCHEMBL6791925

COC(=O)CNS(=O)(=O)c1ccc2cc(Cl)ccc2c1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
GAA P10253 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
KDM4E B2RXH2 2/20 0.57
NPC1 O15118 1/20 0.57
HPGD P15428 1/20 0.57
RAB9A P51151 1/20 0.57
KAT6A Q92794 3/20 0.49
MMP1 P03956 1/20 0.48
CTSS P25774 1/20 0.47
POLB P06746 1/20 0.46
MEP1B Q16820 3/20 0.45
TSHR P16473 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MAPT P10636 1/20 0.43
FLT1 P17948 1/20 0.42
FLT4 P35916 1/20 0.42
KDR P35968 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6079464 0.88 ALDH1A1 (0.53) ALDH1A1GAASMN1; SMN2KDM4ENPC1
SCHEMBL5729430 0.87 ACACB (0.47) ALDH1A1GAASMN1; SMN2KDM4ENPC1
SCHEMBL28677877 0.85 KDM4E (0.71) ALDH1A1GAASMN1; SMN2KDM4ENPC1
SCHEMBL3905853 0.84 APEX1 (0.57) ALDH1A1GAAKDM4EKAT6AMMP1
SCHEMBL7598374 0.83 NPC1 (0.47) ALDH1A1NPC1KAT6AMMP1CTSS
SCHEMBL7012908 0.80 GAA (0.55) ALDH1A1GAAKDM4ENPC1HTT
SCHEMBL5729827 0.78 KMT2A (0.52) ALDH1A1GAAPOLBTSHRMAPT
SCHEMBL3932801 0.78 GAA (0.57) ALDH1A1GAASMN1; SMN2KDM4ENPC1
SCHEMBL7010697 0.77 F10 (0.47) ALDH1A1KDM4EHPGD
SCHEMBL6080098 0.76 ALDH1A1 (0.58) ALDH1A1GAAPOLBHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730672-B2 PROTEASE INHIBITOR ZENECA LIMITED (GB) 2004-05-04 US disclosed
US-20020119968-A1 Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents ZENECA LIMITED 2002-08-29 US disclosed
US-6225309-B1 Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents ZENECA LIMITED (GB) 2001-05-01 US disclosed
US-5965559-A STRONG INHIBITORY EFFECT AGAINST THE ACTIVATED COAGULATION PROTEASE KNOWN AS FACTOR XA; PREVENTION OF THE CLEAVAGE OF PROTHROMBIN TO THROMBIN; AMINO-SUBSTITUTED PYRIMIDINES AMIDINE GROUP-FREE ZENECA LIMITED (GB) 1999-10-12 US disclosed
EP-0783500-A1 AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS ZENECA LIMITED (GB) 1997-07-16 EP disclosed
WO-1996010022-A1 AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS ZENECA LIMITED (GB) 1996-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119968-A1 Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents SERPINC1, F2, SULT1E1 ALDH1A1 1423/4885GAA 4480/4885SMN1; SMN2 2956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.